# Guideline-concordance along the cancer care continuum and breast cancer mortality by race and ethnicity: a SEER-Medicare study

**Authors:** Emma L. Herbach, Ryan M. Carnahan, Lauren E. McCullough, Bradley D. McDowell, Michaela Curran, Kai Wang, Ingrid M. Lizarraga, Mary E. Charlton, Sarah H. Nash

PMC · DOI: 10.1007/s10552-025-02099-9 · 2026-01-21

## TL;DR

This study finds that following cancer care guidelines reduces breast cancer deaths, but the benefits vary by race and ethnicity.

## Contribution

The study examines how adherence to cancer care guidelines affects mortality across different racial and ethnic groups.

## Key findings

- Non-concordant care increases breast cancer mortality risk for most racial/ethnic groups.
- Locoregional treatment adherence is strongly linked to lower mortality across all groups.
- Disparities persist despite guideline adherence, highlighting structural inequities.

## Abstract

To examine the relationship between guideline-concordant breast cancer care and hazard of cancer death by patient race and ethnicity.

We used SEER-Medicare data to identify 212,555 older women diagnosed with invasive breast cancer between 2000 and 2017. Guideline-concordant diagnostic workup, locoregional treatment, and initiation of systemic therapy were defined using NCCN guidelines. Hazards of breast cancer death 2 and 5 years from diagnosis by each guideline-concordance outcome overall and stratified by race and ethnicity were estimated using Cox proportional hazards models.

Non-concordant diagnostic workup, locoregional treatment, and systemic therapy initiation were each associated with increased hazards of 2- and 5-year breast cancer mortality (diagnostics HR2-year (95% CI) 1.33 (1.25–1.41), HR5-year 1.29 (1.23–1.35); locoregional HR2-year 2.10 (1.98–2.23), HR5-year 1.83 (1.76–1.90); systemics HR2-year 1.67 (1.51–1.84), HR5-year 1.56 (1.45–1.68)). Non-concordant diagnostic workup and systemic therapy initiation were associated with greater hazard of 2- and 5-year breast cancer death among Black, Asian/Pacific Islander, Hispanic White, and non-Hispanic White patients; there was no consistent association among American Indian/Alaska Native patients for either outcome. Locoregional treatment was strongly associated with hazards of cancer death for all groups.

Equitable delivery of guideline-recommended breast cancer care from diagnosis through treatment across racial and ethnic groups may mitigate survival disparities. Efforts to improve access to high-quality care must be informed by and responsive to the social and structural root causes of health inequities.

The online version contains supplementary material available at 10.1007/s10552-025-02099-9.

## Linked entities

- **Diseases:** breast cancer (MONDO:0004989)

## Full-text entities

- **Genes:** NR4A1 (nuclear receptor subfamily 4 group A member 1) [NCBI Gene 3164] {aka GFRP1, HMR, N10, NAK-1, NGFIB, NP10}, ERBB2 (erb-b2 receptor tyrosine kinase 2) [NCBI Gene 2064] {aka CD340, HER-2, HER-2/neu, HER2, MLN 19, MLN-19}, TENM1 (teneurin transmembrane protein 1) [NCBI Gene 10178] {aka ODZ1, ODZ3, TEN-M1, TEN1, TNM, TNM1}
- **Diseases:** inflammatory carcinoma (MESH:D058922), API (MESH:D007516), Cancer (MESH:D009369), nodal (MESH:D013611), Paget disease (MESH:C537701), Frailty (MESH:D000073496), AIAN (MESH:C538343), breast cancer (MESH:D001943), Phyllodes tumors (MESH:D003557), AIDS (MESH:D000163), death (MESH:D003643), cardiovascular, pulmonary, neurologic, renal, liver, and rheumatologic diseases (MESH:D002318), Comorbidity (MESH:D004194), diabetes (MESH:D003920), Metastasis (MESH:D009362)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Figures

4 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12823728/full.md

---
Source: https://tomesphere.com/paper/PMC12823728